4.4 Article

Global trends in molecular epidemiology of HIV-1 during 2000-2007

期刊

AIDS
卷 25, 期 5, 页码 679-689

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e328342ff93

关键词

circulating recombinant form; HIV; molecular epidemiology; recombinant; subtype; vaccine

资金

  1. National Institute of Health Research (NIHR), UK
  2. Medical Research Council [MC_U950097144] Funding Source: researchfish
  3. MRC [MC_U950097144] Funding Source: UKRI

向作者/读者索取更多资源

Objective: To estimate the global and regional distribution of HIV-1 subtypes and recombinants between 2000 and 2007. Design: Country-specific HIV-1 molecular epidemiology data were combined with estimates of the number of HIV-infected people in each country. Methods: Cross-sectional HIV-1 subtyping data were collected from 65 913 samples in 109 countries between 2000 and 2007. The distribution of HIV-1 subtypes in individual countries was weighted according to the number of HIV-infected people in each country to generate estimates of regional and global HIV-1 subtype distribution for the periods 2000-2003 and 2004-2007. Results: Analysis of the global distribution of HIV-1 subtypes and recombinants in the two periods indicated a broadly stable distribution of HIV-1 subtypes worldwide with a notable increase in the proportion of circulating recombinant forms (CRFs), a decrease in unique recombinant forms (URFs) and an overall increase in recombinants. In 20042007, subtype C accounted for nearly half (48%) of all global infections, followed by subtypes A (12%) and B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) and D (2%). Subtypes F, H, J and K together cause fewer than 1% of infections worldwide. Other CRFs and URFs are each responsible for 4% of global infections, bringing the combined total of worldwide CRFs to 16% and all recombinants (CRFs along with URFs) to 20%. Conclusion: The global and regional distributions of individual subtypes and recombinants are broadly stable, although CRFs may play an increasing role in the HIV pandemic. The global diversity of HIV-1 poses a formidable challenge to HIV vaccine development. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据